Bioxytran, Inc.
BIXT
$0.109
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -77.98% | -2.53% | -55.89% | -32.89% | 23.07% |
| Depreciation & Amortization | -5.00% | -23.68% | -16.67% | -31.82% | 300.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.83% | -51.56% | -64.78% | -42.36% | 4.06% |
| Operating Income | 33.83% | 51.56% | 64.78% | 42.36% | -4.06% |
| Income Before Tax | -135.90% | 50.86% | 66.08% | 54.30% | 29.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -135.90% | 50.86% | 66.08% | 54.30% | 29.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -38.99% | -- | -- | -59.57% |
| Net Income | -141.50% | 51.11% | 65.03% | 54.28% | 28.61% |
| EBIT | 33.83% | 51.56% | 64.78% | 42.36% | -4.06% |
| EBITDA | 33.89% | 51.67% | 64.87% | 42.38% | -3.87% |
| EPS Basic | -347.06% | 22.86% | 62.20% | 66.96% | 46.88% |
| Normalized Basic EPS | -216.67% | -53.49% | 62.00% | 67.14% | 23.08% |
| EPS Diluted | -347.06% | 22.86% | 62.20% | 66.96% | 46.88% |
| Normalized Diluted EPS | -216.67% | -53.49% | 62.00% | 67.14% | 23.08% |
| Average Basic Shares Outstanding | -45.65% | -37.03% | -7.37% | 37.11% | 32.35% |
| Average Diluted Shares Outstanding | -45.65% | -37.03% | -7.37% | 37.11% | 32.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |